Genomic Profile of Breast Cancer: Cost-effectiveness Analysis from the Spanish National Healthcare System Perspective

Publication Name: Expert Review of Pharmacoeconmics & Outcomes Research

Author(s): Miguel Ángel Seguí, Carlos Crespo, Javier Cortés, Ana Lluch, Max Brosa, Virginia Becerra, Sebastián Matias Chiavenna, and Alfredo Gracia

Background: Cost–effectiveness analysis of MammaPrint® (70-gene signature) in the diagnosis of early breast cancer as a prognosis assay to study the risk of tumor recurrence to administer adjuvant chemotherapy. Methods: Markov model assuming a cohort of 60-year-old women with breast cancer. … Continued

Cost Effectiveness of Gene Expression Profiling for Early Stage Breast Cancer

Publication Name: Cancer

Author(s): Mo Yang, MS; Suja Rajan, PhD; and Amalia M. Issa, PhD, MPH

BACKGROUND: Gene expression profiling (GEP) is being used increasingly for risk stratification to identify women with lymph nodenegative, estrogen receptor-positive, early stage breast cancer who are most likely to benefit from adjuvant chemotherapy. The authors of this report evaluated the … Continued

Head-to-head comparison of the 70-gene signature versus the 21-gene assay: cost-effectiveness and the effect of compliance

Publication Name: Breast Cancer Research and Treatment

Author(s): Valesca P. Retel, Manuela A. Joore, Wim H. van Harten

Both the 70-gene signature and the 21-gene assay are novel prognostic tests used to guide adjuvant chemotherapy decisions in patients with early breast cancer. Although the results of ongoing prospective trials will only become available in some years, the tests … Continued

Cost-Effectiveness of 70-Gene MammaPrint Signature in Node-Negative Breast Cancer

Publication Name: The American Journal of Managed Care

Author(s): Er Chen, MPP; Kuo Bianchini Tong, MS; and Jennifer L. Malin, MD, PhD

Objective: To evaluate the cost-effectiveness of 70-gene MammaPrint signature (Agendia Inc, Huntington Beach, CA) vs Adjuvant! Online soft ware (AS) (http://www.adjuvantonline.com) in patients 60 years or younger with early-stage breast cancer. Study Design: Cost-effectiveness and cost-utility analyses from a US … Continued

Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer

Publication Name: European Journal of Cancer

Author(s): Valesca Retel, MA Joore, WH van Harten

Background: The 70-gene signature (MammaPrint) is a prognostic test used to guide adjuvant treatment decisions in patients with node-negative breast cancer. In order to decide upon its use, a systematic comparative analysis of the effects of the 70-gene signature,the Saint … Continued

Frequency and Cost of Chemotherapy-Related Serious Adverse Effects in a Population Sample of Women With Breast Cancer

Publication Name: Journal of the National Cancer Institute

Author(s): Michael J. Hassett , A. James O’Malley , Juliana R. Pakes , Joseph P. Newhouse , Craig C. Earle

Background: The number, nature, and costs of serious adverse effects experienced by younger women receiving chemotherapy for breast cancer outside of clinical trials are unknown. Methods: From a database of medical claims made by individuals with employer-provided health insurance between … Continued